More details
Hide details
Z Zakładu Biologii Medycznej Instytut Medycyny Wsi im. W. Chodźki w Lublinie
Med Og. 2009;15(4):566–575
Kynurenic pathway is the main non-protein route of the conversion of tryptophan. For many years, an interest in this pathway was limited to the synthesis of the nicotinic acid, which is a substrate for the basic enzymatic reaction cofactor – NAD. However, indirect metabolites of the kynurenic pathway are also important, which exert an effect on such processesand phenomena as: proliferation of cells, regulation of anti- and pro-oxidants, excytotoxicity, neurodegradation or inflammatory processes. One of the metabolites of the kynurenic pathway is kynurenic acid. This acts as an antagonist towards all types of glutomineralgic receptors, and may also regulate peripheral cellular response by the activation of GPR35 receptors. Its role outside the nervous system remains unclear, despite the fact that its presence was observed in many body fluids. It was also detected in the lumen of the intestine, where intestinal bacterial flora seems to be its main producer. KYNA also occurs in many food products and may be absorbed from the alimentary tract into bloodstream.
Allegri G, Costa CV, Bertazzo A, Biasiolo M, Ragazzi E.: Enzyme activities of tryptophan metabolism along the kynurenine pathway in various species of animals. Farmaco., 2003, 58, 829-836.
Baran H, Staniek K, Kepplinger B, Stur J, Draxler M, Nohl H.: Kynurenines and the respiratory parameters of rat heart mitochondria. Life Sciences 2003, 72, 1103-1115.
Bozza S, Fallarino F, Pitzurra L, Zelante T, Montagnoli C, Bellocchio S, Mosci P, Vacca C, Puccetti P, Romani L.: A crucial role for tryptophan catabolism at the host/Candida albicans interface. J Immunol. 2005, 174, 2910-2918.
Clarke G, Fitzgerald P, Cryan JF, Cassidy EM, Quigley EM, Dinan TG.: Tryptophan degradation in irritable bowel syndrome: evidence of indoleamine 2,3-dioxygenase activation in a male cohort. BMC Gastroenterol. 2009, 9, 6.
Grohmann U, Fallarino F, Bianchi R, Orabona C, Vacca C, Fioretti MC, Puccetti P.: A defect in tryptophan catabolism impairs tolerance in nonobese diabetic mice. J Exp Med. 2003, 198, 153-160.
Guo J, Williams DJ, Puhl HL 3rd, Ikeda SR.: Inhibition of N-type calcium channels by activation of GPR35, an orphan receptor, heterologously expressed in rat sympathetic neurons. J Pharmacol Exp Ther. 2008, 324, 342-351.
Han Q, Fang J, Li J.: Kynurenine aminotransferase and glutamine transaminase K of Escherichia coli: identity with aspartate aminotransferase. Biochem J 2001, 360, 617–623.
Hayashi T, Beck L, Rossetto C, Gong X, Takikawa O, Takabayashi K, Broide DH, Carson DA, Raz E.: Inhibition of experimental asthma by indoleamine 2,3-dioxygenase. J Clin Invest. 2004, 114, 270-279.
Heyes MP, Saito K, Crowley JS, Davis LE, Demitrack MA, Der M, Dilling LA, Elia J, Kruesi MJ, Lackner A.: Quinolinic acid and kynurenine pathway metabolism in inflammatory and non-inflammatory neurological disease. Brain. 1992, 115, 1249-1273.
Kazda H, Taylor N, Healy D, Walker D.: Maternal, umbilical, and amniotic fluid concentrations of tryptophan and kynurenine after labor or cesarean section. Pediatr Res 1998, 44, 368–373.
Kuc D, Zgrajka W, Parada-Turska J, Urbanik-Sypniewska T, Turski WA.: Micromolar concentration of kynurenic acid in rat small intestine. Amino Acids 2008, 35, 503-505.
Kudo Y, Boyd CA, Sargent IL, Redman CW.: Tryptophan degradation by human placental indoleamine 2,3-dioxygenase regulates lymphocyte proliferation. J Physiol. 2001, 535, 207-215.
Löb S, Königsrainer A.: Is IDO a key enzyme bridging the gap between tumor escape and tolerance induction? Langenbecks Arch Surg. 2008, 393, 995-1003.
Mellor AL, Munn DH.: IDO expression by dendritic cells: tolerance and tryptophan catabolism. Nat Rev Immunol. 2004, 4, 762-774.
Milart P, Urbanska EM, Turski WA, Paszkowski T, Sikorski R: Kynurenine aminotransferase I activity in human placenta. Placenta 2001, 22, 259–261.
Moffett JR, Namboodiri MA.: Tryptophan and the immune response. Immunol Cell Biol. 2003, 81, 247-265.
Parada-Turska J, Rzeski W, Zgrajka W, Majdan M, Kandefer-Szerszen M, Turski W.: Kynurenic acid, an endogenous constituent of rheumatoid arthritis synovial fluid, inhibits proliferation of synoviocytes in vitro. Rheumatol Int 2006, 26, 422–426.
Pawlak D, Pawlak K, Malyszko J, Mysliwiec M, Buczko W.: Accumulation of toxic products degradation of kynurenine in hemodialyzed patients. Int Urol Nephrol. 2001, 33, 399-404.
Pérez-De La Cruz V, Königsberg M, Santamaría A.: Kynurenine pathway and disease: an overview. CNS Neurol Disord Drug Targets.2007, 6, 398-410.
Riesenberg R, Weiler C, Spring O, Eder M, Buchner A, Popp T, Castro M, Kammerer R, Takikawa O, Hatz RA, Stief CG, Hofstetter A, Zimmermann W.: Expression of indoleamine 2,3-dioxygenase in tumor endothelial cells correlates with long-term survival of patients with renal cell carcinoma. Clin Cancer Res. 2007, 13, 6993-7002.
Russo M, Tedesco I, Iacomino G, Palumbo R, Galano G, Russo GL.: Dietary phytochemicals in chemoprevention of cancer. Curr. Med. Chem. – Immun.2005, 5, 61-72.
Rzeski, W., Turski, L. Ikonomidou, C.: Glutamate antagonists limit tumour growth. Proc. Natl Acad. Sci USA 2001, 98, 6372–6377.
Smith AJ, Stone TW, Smith RA.: Neurotoxicity of tryptophan metabolites. Biochem Soc Trans. 2007, 35, 1287-1299.
Stone TW, Darlington LG.: Endogenous kynurenines as targets for drug discovery and development. Nat Rev Drug Discov. 2002, 1, 609-620.
Stone TW.: Development and therapeutic potential of kynurenic acid and kynurenine derivatives for neuroprotection. Trends Pharmacol Sci. 2000, 21, 149-154.
Stone TW.: Inhibitors of the kynurenine pathway. Eur J Med Chem 2000, 35, 179-186.
Turski MP, Turska M, Zgrajka W, Kuc D, Turski WA.: Presence of kynurenic acid in food and honeybee products. Amino Acids 2009, 36, 75-80.
Wang J, Simonavicius N, Wu X, Swaminath G, Reagan J, Tian H, Ling L.: Kynurenic acid as a ligand for orphan G protein-coupled receptor GPR35. J Biol Chem. 2006, 281, 22021-22028.